Managing GLP-1 Side Effects: Nausea, Reflux, Red Flags

By the Healthy Weight Loss 4 U Clinical Content Team · Published October 8, 2026 · Updated October 8, 2026 · 9 min read

Key takeaways

• In the Wegovy label, 73% of adults on semaglutide 2.4 mg had a gastrointestinal reaction versus 47% on placebo; severe ones were 4.1% versus 0.9% ^[1].
• Trials report that GI effects are mostly mild to moderate and occur mainly during dose escalation, so timing around dose increases matters ^[5].
• Practical guidance from consensus statements: smaller meals, stop at fullness, limit fatty food, alcohol and fizzy drinks, keep fluids up, and add fiber and water for constipation ^[6][8].
• Vomiting or diarrhea can cause dehydration and, rarely, acute kidney injury, so persistent symptoms should be reported early ^[1][3].
• Severe abdominal pain that does not go away, possibly spreading to the back, is a reason to stop the medicine and call a clinician promptly ^[3][6].
• Hair loss is listed in both labels (3% versus 1% for Wegovy; 4% to 5% versus 1% for Zepbound) ^[1][2].

What are the most common GLP-1 side effects, and how often do they happen?

Gastrointestinal effects are the most common side effects of the two weight-management GLP-1 medicines approved in the United States, semaglutide (Wegovy) and tirzepatide (Zepbound). In the label tables below, individual gastrointestinal reactions ranged from about 4% to 44% of adults, depending on the symptom, dose and drug ^[1][2]. In the Wegovy label, 73% of adults taking semaglutide 2.4 mg had a gastrointestinal reaction versus 47% on placebo, and severe gastrointestinal reactions occurred in 4.1% versus 0.9% ^[1]. In the Zepbound label, severe gastrointestinal reactions occurred in 1.7% (5 mg), 2.5% (10 mg) and 3.1% (15 mg) of participants versus 1% on placebo ^[2].

The table below reproduces the label adverse-reaction rates. These come from separate trials with different populations and designs, so they should not be used to rank one drug as better tolerated than the other ^[1][2].

Two published trials add context. In STEP 1 (1,961 adults, 68 weeks), nausea and diarrhea were the most common adverse events, usually mild to moderate and transient, and gastrointestinal events led to stopping treatment in 4.5% of semaglutide participants versus 0.8% on placebo ^[4]. In SURMOUNT-1 (2,539 adults, 72 weeks), the most common adverse events were gastrointestinal, mostly mild to moderate and mainly during dose escalation; adverse events led to discontinuation in 4.3%, 7.1% and 6.2% of the 5 mg, 10 mg and 15 mg groups versus 2.6% on placebo ^[5].

When do side effects start, and how long do they last?

Gastrointestinal side effects tend to appear around dose increases and often ease with time at a stable dose. In SURMOUNT-1 they occurred mainly during the dose-escalation period ^[5], the Zepbound label states that the majority of nausea, vomiting and/or diarrhea events occurred during dose escalation and decreased over time ^[2], and a clinical commentary on managing these effects notes that nausea usually eases after dose escalation ends ^[6].

A multidisciplinary expert consensus gives rough durations: nausea usually moderate and resolving within about 8 days, vomiting within 1 to 8 days, diarrhea starting in the first four weeks and lasting about three days, and constipation lasting longer than the other effects ^[7]. The panel drew these figures from a literature search of trials and real-world studies without grading the evidence, and its work was funded by Novo Nordisk, so treat the numbers as typical patterns rather than promises ^[7].

Both labels build gradual escalation into dosing. The Zepbound label starts at 2.5 mg weekly for 4 weeks and increases in 2.5 mg steps after at least 4 weeks on each dose ^[2]. The Wegovy label states that if a dose is not tolerated during escalation, a clinician can consider delaying escalation for 4 weeks ^[1]. Any change to timing or dose is a decision for the prescribing clinician, not something to adjust alone.

What helps with nausea and vomiting?

Published guidance for nausea centers on how and what you eat. A joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society suggests a small breakfast followed by small meals every 3 to 4 hours with adequate fluids, avoiding large or high-fat meals, avoiding fatty or high-fiber foods during the first few days of treatment, and limiting alcohol ^[8]. It also lists ginger or peppermint tea and acupressure bands as options that may help ^[8].

A commentary by obesity specialists (its medical writing support was funded by Novo Nordisk) adds practical points: eat smaller portions and stop once full, avoid eating when not hungry, avoid high-fat or spicy food especially during escalation, and limit alcohol and carbonated drinks if nausea or dyspepsia occurs ^[6]. The same authors state that evidence on managing these side effects is limited and that most recommendations reflect clinical experience ^[6]. They also prefer dose reduction over anti-nausea drugs, reserve short-term antiemetics for selected patients, and suggest reconsidering the dose if symptoms need treatment for more than a month at maintenance dose ^[6].

What helps with constipation, diarrhea and reflux?

For constipation, the joint advisory advises adequate fluids and fiber from foods, increased gradually, with a fiber supplement if diet alone is not enough, and mentions daily magnesium supplementation titrated to keep bowel movements regular ^[8]. The Wharton commentary likewise suggests more fiber and water and consideration of stool softeners ^[6], and the expert consensus adds increasing mobility ^[7]. Constipation is common: 24% on Wegovy 2.4 mg and 11% to 17% on Zepbound in the label tables ^[1][2].

For diarrhea, the consensus recommends dietary measures first, with probiotics or loperamide considered by a clinician if it persists, and notes that metformin can contribute in people who take it ^[7]. For reflux, the commentary advises treating underlying gastroesophageal reflux disease, says a proton-pump inhibitor or H2 blocker may be considered temporarily during escalation, and notes that reflux can also improve with weight loss ^[6]. In the label tables reflux was reported by 5% on Wegovy and 4% to 5% on Zepbound ^[1][2]. Ask your clinician before adding over-the-counter remedies, especially if you take other medicines.

How do GLP-1 medicines cause dehydration, and why does it matter?

Persistent vomiting or diarrhea can cause fluid loss, which can lead to acute kidney injury. In the Wegovy trials acute kidney injury occurred in 7 adults (0.4 per 100 patient-years) versus 4 on placebo (0.2), and the label states that most reported cases involved gastrointestinal reactions leading to dehydration ^[1]. The Zepbound label reports acute kidney injury in 0.5% versus 0.2% on placebo ^[2]. Both labels advise monitoring kidney function in patients who report reactions that could lead to volume depletion ^[1][2].

The Zepbound Medication Guide says diarrhea, nausea and vomiting may cause a loss of fluids that may cause kidney problems, and tells patients to contact a provider if these symptoms do not go away ^[3]. The joint advisory recommends counseling patients to drink adequate fluids, especially with nausea, vomiting or diarrhea ^[8]. Specialists describe vomiting that is excessive and accompanied by dizziness, confusion and fatigue as a reason for more urgent care ^[6].

Do GLP-1 medicines cause hair loss or fatigue?

Both are listed adverse reactions, at modest rates. Hair loss was reported by 3% of adults on Wegovy 2.4 mg versus 1% on placebo, and the Wegovy label links it to weight reduction ^[1]. In the Zepbound label hair loss was 5% (5 mg), 4% (10 mg) and 5% (15 mg) versus 1% on placebo ^[2]. The label tables give frequencies; they do not specify how long hair loss lasts or whether it reverses.

Fatigue was reported by 11% on Wegovy versus 5% on placebo, and by 5%, 6% and 7% across Zepbound doses versus 3% ^[1][2]. The labels do not establish a cause. Fatigue or hair changes that are persistent, severe or accompanied by other symptoms are worth raising with a clinician, who can check intake, hydration and other contributors.

What are the gallbladder and pancreatitis warning signs?

Gallbladder disease and pancreatitis are uncommon but serious. In the Wegovy trials cholelithiasis (gallstones) occurred in 1.6% of adults versus 0.7% on placebo and cholecystitis in 0.6% versus 0.2% ^[1]. In the Zepbound label cholelithiasis was 1.1% versus 1% and cholecystitis 0.7% versus 0.2%, with cholecystectomy in 0.2% of Zepbound patients and none on placebo ^[2]. Adjudicated acute pancreatitis occurred in 4 Wegovy-treated adults (0.2 per 100 patient-years) versus 1 on placebo ^[1], and in 0.2% of both Zepbound and placebo groups ^[2].

The Zepbound Medication Guide describes warning signs. For pancreatitis: severe pain in the stomach area that will not go away, which may spread to the back. For gallbladder problems: upper abdominal pain, yellowing of the skin or eyes, fever or clay-colored stools ^[3]. The labels direct stopping the medicine if pancreatitis is suspected, and clinicians recommend not restarting if it is confirmed ^[1][6]. If gallstones are suspected, gallbladder studies and follow-up are indicated ^[6].

When should you get urgent medical care?

Seek prompt medical care for the symptoms below, and call emergency services for severe or rapidly worsening symptoms. This list is general information drawn from labeling and published guidance, not a substitute for your clinician's instructions.

• Severe abdominal pain that will not go away, with or without vomiting, possibly spreading to the back: possible pancreatitis; the medicine should be stopped and a clinician called promptly ^[3][6].
• Upper abdominal pain with fever, yellowing of the skin or eyes, or clay-colored stools: possible gallbladder problems ^[3].
• Vomiting or diarrhea that does not go away, especially with dizziness, confusion or marked fatigue: possible dehydration and kidney strain ^[3][6].
• Swelling of the face, lips, tongue or throat, trouble breathing or swallowing, fainting, a very rapid heartbeat, or a severe rash or itching: possible serious allergic reaction; stop the medicine and get medical help right away ^[3].
• Any planned surgery or procedure using anesthesia or deep sedation: tell every provider that you take the medicine, because rare postmarketing reports describe residual stomach contents despite fasting in patients having surgery or deep sedation ^[2][3].

What this means in practice

Most people who take a GLP-1 weight-management medicine should expect some gastrointestinal effects, most likely around dose increases, and should know what to do about them before the first dose. The published strategies are low-risk and food-based: small meals, stopping at fullness, limiting fatty food, alcohol and fizzy drinks, steady fluids, and fiber from food for constipation ^[6][8]. The higher-stakes decisions, such as pausing escalation, lowering a dose or stopping, belong to a licensed clinician who knows your history ^[1][6].

Side-effect rates in this article come from the labels of FDA-approved products. The FDA states that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before they are marketed; it has also received adverse event reports, some related to dosing errors, for compounded semaglutide and tirzepatide ^[9].

At Healthy Weight Loss 4 U, every program begins with a clinician evaluation at the Lighthouse Point, FL and Highlands Ranch, CO clinics. Bring your medication list, any history of pancreatitis, gallbladder disease or kidney problems, and your questions about side effects to that visit.

Frequently asked questions

Sources

1. WEGOVY (semaglutide) injection and tablets: Prescribing Information (revised 06/2026). Novo Nordisk, 2026. novo-pi.com/wegovy.pdf
2. ZEPBOUND (tirzepatide) injection: Full Prescribing Information (revised 8/2026). Eli Lilly and Company, 2026. uspl.lilly.com/zepbound/zepbound.html
3. ZEPBOUND Medication Guide (revised 08/2026). Eli Lilly and Company, 2026. pi.lilly.com/us/zepbound-us-mg.pdf
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). The New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). The New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2206038
6. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine 134(1):14-19 (Wharton et al.), 2022. doi.org/10.1080/00325481.2021.2002616
7. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine 12(1):145 (Gorgojo-Martinez et al.), 2023. mdpi.com/2077-0383/12/1/145
8. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the ACLM, ASN, OMA and The Obesity Society. American Journal of Lifestyle Medicine (Mozaffarian et al.), 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12125019/
9. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. fda.gov/drugs/postmarket-drug-safety-information-patients-and-provider

Keep reading